Research & Development
Blue Earth Diagnostics Notes First Production and Administration of Axumin in France.
13 December 2018 - - UK-based molecular imaging diagnostics company Blue Earth Diagnostics said the first commercial production of Axumin (fluciclovine) in France occurred recently, with the first French patients being dosed.

Axumin is a novel molecular imaging agent approved in the European Union for use in PET imaging to detect and localise prostate cancer in men experiencing suspected recurrence based on elevated blood prostate specific antigen levels after primary curative treatment.

It is the first and only PET imaging agent approved by the European Commission for use in men with suspected recurrent prostate cancer in all European Union member states as well as in Iceland, Liechtenstein and Norway.

Axumin is commercially available in France, Norway, the Czech Republic, The Netherlands, United Kingdom and Austria with further European countries set to follow soon.

Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need.

Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products.

The company's first approved and commercially available product is Axumin (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localiSe prostate cancer in men with a diagnosis of biochemical recurrence.

The company's pipeline includes Prostate Specific Membrane Antigen -targeted radiohybrid agents. rhPSMA is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. 

Blue Earth Diagnostics is backed by Syncona, an investment company (LON: SYNC).
Login
Username:

Password: